DNDi aims to deliver:

  • A safe, effective, and easy-to-use direct-acting antiviral regimen, to be used as an affordable combination paving the way for a public health approach to hepatitis C.
  • Increased access to affordable treatments by supporting policy change and encouraging political will to treat hepatitis C.
  • Innovative programmes to improve access to hepatitis C diagnosis and treatment in a variety of countries.


The current hepatitis C portfolio includes:



Ravidasvir + sofosbuvir


For more details on each project, see DNDi‘s Global Portfolio